The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

Country Sites U.S. Residents

Plaque  Psoriasis

Plaque  Psoriasis

Clinical Efficacy

Clinical Efficacy

Safety

Safety

Dosing

Dosing

Mechanism of Action

Mechanism of Action

Testimonials

Testimonials

About Psoriasis

About Psoriasis

Resources

Resources

Psoriatic  Arthritis

Psoriatic  Arthritis

Clinical Efficacy

Clinical Efficacy

Safety

Safety

Dosing

Dosing

Mechanism of Action

Mechanism of Action

About Psoriatic Arthritis

About Psoriatic Arthritis

Treatment Recommendations

Treatment Recommendations

Resources

Resources

CONSIDER ORAL OTEZLA FOR YOUR PSORIASIS PATIENTS

Oral psoriasis treatment options1
 
OTEZLA
Skilarence®
Methotrexate
Acitretin
Cyclosporine
Treatment considerations
Indicated for PsO and PsAtable-checktable-crosstable-checktable-crosstable-cross
Titration period5 daysUp to 9 weekstable-checkUp to 8 weekstable-cross
No label-required laboratory prescreening or ongoing monitoring*table-checktable-crosstable-crosstable-crosstable-cross
Warnings and precautions
  • -Diarrhea
  • -Nausea
  • -Vomiting
  • -Psychiatric disorders
  • -Severe renal impairment
  • -Pregnancy
  • -Underweight patients
  • -Lactose content
  • -Decreased blood cell counts
  • -Opportunistic infections/PML
  • -Severe gastrointestinal disorders
  • -Severe hepatic or renal impairment
  • -Fanconi syndrome
  • -Pregnancy or nursing
  • -Liver function abnormalities
  • -Alcohol use
  • -Active infectious disease
  • -Immunosuppression
  • -Diabetes mellitus
  • -Pregnancy
  • -Significant hematologic abnormalities
  • -Pregnancy category Xa
  • -Severe liver failure
  • -Severe kidney failure
  • -Alcohol use
  • -Lymphomas
  • -Skin malignancy
  • -Infections (including opportunistic)
  • -Renal toxicity
  • -Hepatoxicity
  • -Hypertension
  • -Hyperkaelemia
  • -Neurotoxicity
  • -Pregnancy
  • -Alcohol use

aPregnancy category X (contraception starting 1 month before treatment and 2-year wait period after cessation to become pregnant).

*Regular monitoring is recommended for patients who are underweight at the start of treatment.

Reference:

  1. Data on file, Amgen Inc.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*

  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.